Erratum to: Anti-Inflammatory Strategies for Plaque Stabilization after Acute Coronary Syndromes

Amos Baruch • Nicholas van Bruggen •
Juyong Brian Kim • Joshua E. Lehrer-Graiwer

Published online: 20 October 2013
© Springer Science+Business Media New York 2013

Erratum to: Curr Atheroscler Rep. 2013;15(6):327
DOI 10.1007/s11883-013-0327-7

In this article, CSL112, an HDL-infusion therapy in clinical development has been incorrectly described as a synthetic reconstituted HDL mimetic currently in a Phase 2 IVUS plaque regression study.

Correction: CSL112 is a novel formulation of apoA-I purified from human plasma and reconstituted with phospholipids to form HDL particles suitable for intravenous infusion [1]. CSL112 is currently in a Phase II study with safety and pharmacokinetic endpoints in patients with atherothrombotic disease (NCT01499420).

References

1. Diditchenko S, Gille A, Pragst I, Stadler D, Waelchli M, Hamilton R, et al. Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux. *Arterioscler Thromb Vasc Biol.* 2013;33(9):2202–11.

The online version of the original article can be found at <http://dx.doi.org/10.1007/s11883-013-0327-7>.

A. Baruch • N. van Bruggen • J. E. Lehrer-Graiwer (✉)
Genentech Research and Early Development, 1 DNA Way MS 453a,
South San Francisco, CA 94080, USA
e-mail: lehrer.josh@gene.com

J. B. Kim
Division of Cardiology, Stanford University Department of
Medicine, Stanford, CA, USA